Nivolumab for perioperative esophageal and gastroesophageal cancer: CheckMate 577

(3:12)

Checkmate 577 - Is Nivolumab adjuvant the standard of care in esophagus and GEJ?

(13:47)

Checkmate577: nivolumab in EC/GEJC

(5:18)

Adjuvant Nivolumab in Patients with Resected Esophageal or GEJ Cancer (CheckMate 577)

(4:14)

Adjuvant nivolumab in resected oesophageal or GOJ cancer following chemo

(9:10)

Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020

(3:42)

Jaffer Ajani, MD, shares thoughts on the CheckMate 577 study presented at ESMO 2020

(2:19)

Nivolumab for oesophageal cancer following chemoradiation therapy

(8:16)

Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal/GEJ Cancer

(1:19)

Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting

(11:12)

Can nivolimumab aid in preventing gastrointestinal cancer progression?

(1:56)

Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer

(3:47)

Neoadjuvant nivolumab + chemo continues to provide long-term clinical benefit for NSCLC patients

(5:10)

Dr. Ko Discusses the CheckMate-577 Trial

(1:31)

Nivolumab chemotherapy combination treatment: CheckMate649 and ATTRACTION-4

(4:47)

29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCC

(1:19)

CheckMate 205: 5 year follow-up of nivolumab in HL

(1:48)

Adjuvant nivolumab in patents with high-risk resected melanoma

(2:22)

CheckMate 67T and the Potential of Subcutaneous Nivolumab Administration

(5:33)

CheckMate-77T: Perioperative nivolumab benefit for NSCLC

(14:5)